Antibody Information
General Information of This Antibody
| Antibody ID | ANI0XFVWL |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | IL13Ralpha2-AB08-v1.0/1.2 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1 |
|||||
| Antigen Name | Interleukin-13 (IL13) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
hu08-Malpeg-3906 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 31.10% | Positive IL13 expression (IL13+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
|
||||
| In Vivo Model | PC3-MM2 CDX model | ||||
| In Vitro Model | Prostate carcinoma | PC3-MM2 cells | CVCL_4885 | ||
hlgG8.8-mc-3377 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 52.40% | Positive IL13 expression (IL13+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
|
||||
| In Vivo Model | PC3-MM2 CDX model | ||||
| In Vitro Model | Prostate carcinoma | PC3-MM2 cells | CVCL_4885 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 71.90% | Positive IL13 expression (IL13+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
|
||||
| In Vivo Model | A-375 CDX model | ||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 72.40% | Positive IL13 expression (IL13+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 3 mg/kg, Q4d*4 to thetail of each mouse.
|
||||
| In Vivo Model | A-375 CDX model | ||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 400 ug/mL | Negative IL13 expression (IL13-) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Lung large cell carcinoma | NCI-H460 cells | CVCL_0459 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 400 ug/mL | Negative IL13 expression (IL13-) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Amelanotic melanoma | A-375 cells | CVCL_0132 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 400 ug/mL | Positive IL13 expression (IL13+++/++) | ||
| Method Description |
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.
Click to Show/Hide
|
||||
| In Vitro Model | Prostate carcinoma | PC3-MM2 cells | CVCL_4885 | ||
hlgG8.84-mc-3377 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 72.50% | Positive IL13 expression (IL13+++/++) | ||
| Method Description |
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 10 mg/kg, Q4d*4 to thetail of each mouse.
|
||||
| In Vivo Model | PC3-MM2 CDX model | ||||
| In Vitro Model | Prostate carcinoma | PC3-MM2 cells | CVCL_4885 | ||